CLL-1 and CD33 expression and cytolytic activity of ABL602 2+1 on AML blasts
| Patient number | In CD45+ cells | In AML blasts | Cytotoxicity to CLL-1+ AML cells (EC50, pM) | |||||
| AML blasts (%) | CD3+ T cells (%) | E:T ratio | CLL-1+ cells (%) | CD33+ cells (%) | CLL-1 expression (relative MFI) | CD33 expression (relative MFI) | ||
| 3 | 58.25 | 1.66 | 1:35 | 95.31 | 85.9 | 10.09 | 4.65 | ND |
| 4 | 25.76 | 0.094 | 1:274 | 98.98 | 99.1 | 11.99 | 9.51 | ND |
| 5 | 20.67 | 36.54 | 1:0.57 | 6.16 | 38.3 | 0.48 | 6.97 | ND |
| 6 | 0.4 | 31.16 | 1:0.013 | 16.19 | 18.67 | 13.49 | 3.55 | ND |
| 7 | 61.36 | 7.15 | 1:8.58 | 89.36 | 97.58 | 28.15 | 36.17 | 140 |
| 8 | 81.98 | 1.565 | 1:52.38 | 97.04 | 98 | 38.55 | 17.39 | 200 |
| 9 | 91.83 | 3.39 | 1:27 | 0.26 | 96.19 | 0.97 | 14.31 | ND |
| 10 | 88.62 | 1.76 | 1:50.35 | 92.93 | 99.33 | 64.83 | 72.70 | 200 |
| 11 | 45.15 | 10.37 | 1:4.35 | 80.96 | 85.93 | 53.74 | 30.02 | 70 |
| 12 | 89.94 | 1.45 | 1:62 | 97.87 | 99.3 | 45.71 | 45.05 | 300 |
| 13 | 9 | 9.32 | 1:0.97 | 11.15 | 14.62 | 1.42 | 1.37 | ND |
AML, acute myeloid leukemia; EC50, half maximal effective concentration; E:T, effector:target; MFI, mean fluorescence intensity; ND, not determined.